Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.86 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alogliptin SCHEMBL30216225 | 1.00 | DPP4 (0.86) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL476232 | 1.00 | DPP4 (0.86) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL16246767 | 1.00 | DPP4 (0.86) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL29352995 | 0.93 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL17036596 | 0.93 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL174188 | 0.93 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL121028 | 0.93 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL475872 | 0.92 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL17781892 | 0.92 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL476292 | 0.91 | DPP4 (0.85) | DPP4OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 628 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118948849-A | Medicine for preventing and treating diseases related to anti-obesity effect | 盐野义制药株式会社 | 2024-11-15 | — | — | CN | claimed |
| US-20240374587-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-11-14 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-115524416-B | Algliptin benzoate and detection method of related substances thereof | 华润双鹤药业股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-20240261447-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO THE HEPATOPANCREATIC ANATOMICAL REGION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-08-08 | — | — | US | claimed |
| EP-4400105-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | Shionogi & Co., Ltd (JP) | 2024-07-17 | — | — | EP | claimed |
| CN-118215478-A | Medicine for preventing and treating diseases related to anti-obesity effect | 盐野义制药株式会社 | 2024-06-18 | — | — | CN | claimed |
| CN-118055778-A | Combination of bitter taste receptor agonist and intestinal signaling compound | 阿达瓦克治疗公司 | 2024-05-17 | — | — | CN | claimed |
| US-11980711-B2 | Inhaler | INHALER LIMITED (GB) | 2024-05-14 | — | — | US | claimed |
| EP-4329812-A1 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | Aardvark Therapeutics Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| CN-110831648-B | Inhaler | 1恩哈勒有限公司 | 2022-04-22 | — | — | CN | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114354802-A | Method for analyzing contents of two cyano bromobenzyl isomers in alogliptin benzoate | 山东大学 | 2022-04-15 | — | — | CN | claimed |
| CN-114213480-A | Novel glycoside compound, pharmaceutical composition, preparation method and application | 中日友好医院(中日友好临床医学研究所) | 2022-03-22 | — | — | CN | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
| CN-114057685-A | Preparation method of alogliptin benzoate with high yield | 西安新通药物研究有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-102134231-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | claimed |
| US-20110306764-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | SANDOZ AG (CH) | 2011-12-15 | — | — | US | claimed |
| EP-2379522-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | Sandoz AG (CH) | 2011-10-26 | — | — | EP | claimed |
| WO-2010072680-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | SANDOZ AG (CH) | 2010-07-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261447-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO THE HEPATOPANCREATIC ANATOMICAL REGION | PNLIP, PYGL, RXFP1 | DPP4 1514/4885OPRM1 397/4885OPRK1 111/4885 |
| US-20110306764-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | CYP3A4, CYP4B1, CYP4X1 | DPP4 37/4885OPRM1 206/4885OPRK1 746/4885 |
| US-20240374587-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | PNLIP, LIPC, GPR119 | DPP4 95/4885OPRM1 3168/4885OPRK1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.